Creso Pharma’s strong quarter marks evolution into a broader-based pharmaceutical company: chairman
The surge in revenue along with business ties-ups across major global markets following regulatory changes and the acquisition of an established psychedelics company could transform it into a broader-based pharma company. CERES Natural Remedies flagship store in Vermont, US
Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has witnessed a strong first quarter, with total revenue rising by 237% from the preceding quarter, marking the company’s evolution into a broader-based pharmaceutical company, according to non-executive chairman Adam Blumenthal.
The surge in the group’s revenue growth during the quarter highlighted the growing demand for the company’s products, as regulatory shifts across cannabis industries globally continue to unlock growth opportunities.